Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Current Deferred Revenue (2016 - 2024)

vTv Therapeutics (VTVT) has disclosed Current Deferred Revenue for 10 consecutive years, with $17000.0 as the latest value for Q3 2024.

  • Quarterly Current Deferred Revenue fell 99.91% to $17000.0 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $17000.0 through Sep 2024, down 99.91% year-over-year, with the annual reading at $18.7 million for FY2023, 109817.65% up from the prior year.
  • Current Deferred Revenue hit $17000.0 in Q3 2024 for vTv Therapeutics, roughly flat from $17000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $18.7 million in Q2 2022 to a low of $17000.0 in Q4 2022.
  • Historically, Current Deferred Revenue has averaged $3.0 million across 5 years, with a median of $31000.0 in 2020.
  • Biggest YoY gain for Current Deferred Revenue was 109817.65% in 2023; the steepest drop was 99.91% in 2023.
  • Year by year, Current Deferred Revenue stood at $31000.0 in 2020, then grew by 12.9% to $35000.0 in 2021, then plummeted by 51.43% to $17000.0 in 2022, then soared by 109817.65% to $18.7 million in 2023, then crashed by 99.91% to $17000.0 in 2024.
  • Business Quant data shows Current Deferred Revenue for VTVT at $17000.0 in Q3 2024, $17000.0 in Q2 2024, and $17000.0 in Q1 2024.